USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Growth Opportunities in Obesity Drugs and Delivery Platforms
GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth
28-Nov-2023
Global
Technology Research
DAD6-01-00-00-00
HC_2023_353
$4,950.00
Special Price $3,712.50 save 25 %
The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases.
People with a body mass index (BMI) of more than or equal to 30 (or 27kg/m2) are classified as obese and may or may not have co-morbidities. Obesity is also known to increase the risk of several diseases, such as type 2 diabetes, cancer mortality, overall mortality, and cardiovascular disorders. It also worsens the prognosis of several diseases and other related co-morbidities.
An active lifestyle with healthy eating practices is crucial for maintaining optimal BMI. Dietary supplementation with fibers, vitamins, minerals, probiotics, and other nutrients can also help manage weight. In addition, healthcare professionals are exploring behavioral interventions for obesity management. Bariatric surgery is the gold standard for obesity treatment. However, recent therapeutic advancement has enabled the launch of oral and injectable drugs for weight loss. GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.
In this study, Frost & Sullivan analyzes the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies. We also provide insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Obesity Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Overview of Noncommunicable Diseases (NCDs)
Scope
Segmentation
Growth Drivers
Growth Restraints
Overview of Approved Obesity Drugs
Game Changers for Obesity Management
Addressing the Challenges of Blockbuster Obesity Drugs
Overview of the Obesity Clinical Trial Landscape
Pipeline Analysis of Obesity Drugs
Regulatory Landscape Overview for Anti-Obesity Drugs: The United States and Europe
Major Emerging GLP-based Dual Receptor Agonists
Major Emerging GLP-based Obesity Drugs in Phase 2 and 3 Clinical Trials
Snapshot of Emerging Non-GLP Obesity Drugs
Snapshot of Emerging Non-GLP Obesity Drugs (continued)
Overview of Drug Delivery Innovations
Features of Drug Delivery Innovations
Snapshot of Emerging Drug Delivery Innovations: Injector Platforms
Snapshot of Emerging Drug Delivery Innovations: Nanomaterial Platforms
Acquisitions by Large Pharma Companies
Pharma Collaborations
Overview of the Funding Landscape for Obesity Drug Delivery
Snapshot of the Partnership Landscape for Obesity Drug Delivery
A Multipronged Approach to Obesity Management
The Future of Drug Delivery Platforms for Obesity Management
Growth Opportunity 1: GLP-1-based Multi-agonists
Growth Opportunity 1: GLP-1-based Multi-agonists (continued)
Growth Opportunity 2: Individualized Treatment Strategy
Growth Opportunity 2: Individualized Treatment Strategy (continued)
Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies
Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| Author | Vandana Iyer |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Obesity Drugs |
| Keyword 2 | Weight Loss Drugs |
| Keyword 3 | Obesity Treatment Drugs |
| Podcast | No |
| WIP Number | DAD6-01-00-00-00 |